Drug design, development and therapyMar 7, 2014

Comparing the effects of switching from candesartan or telmisartan to olmesartan in people with high blood pressure and type 2 diabetes

Circadian Biology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Mar 28, 2026

Abstract

Switching to olmesartan resulted in a significant decrease in clinic blood pressure and morning home blood pressure in hypertensive patients with type 2 diabetes.

A total of 165 patients switched from candesartan and 152 from telmisartan participated in the study.
Clinic blood pressure, morning home diastolic blood pressure, and urinary albumin levels decreased significantly after 16 weeks of olmesartan treatment.
Morning home systolic blood pressure also showed a significant reduction with olmesartan compared to baseline.
After switching back to candesartan or telmisartan, there was a significant increase in clinic blood pressure, morning home blood pressure, and urinary albumin levels.
No adverse reactions requiring withdrawal from the study were reported, and no adverse reactions attributable to the drugs were observed.

Simplified

PURPOSE: This open-label controlled study compared the therapeutic efficacy of three representative angiotensin II receptor blockers (ARBs) in hypertensive patients with type 2 diabetes attending a hospital outpatient clinic. The primary measure in this study was morning home blood pressure (BP).

PATIENTS AND METHODS: Two studies were done concurrently to investigate the effects of switching from two different ARBs to olmesartan. Patients prescribed candesartan (8 mg once daily in the morning) or telmisartan (40 mg once daily in the morning) for 16 weeks were switched to olmesartan (20 mg once daily in the morning) for 16 weeks. Then, they were switched back to candesartan (CO group) or telmisartan (TO group) for another 16 weeks.

RESULTS: Data from all patients in the CO group (n=165) and the TO group (n=152) were analyzed. Clinic and morning home BP and urinary albumin levels showed a significant decrease from baseline at 16 weeks after switching to olmesartan in both the CO and the TO group (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). In contrast, clinic BP, morning home BP, and urinary albumin were significantly increased again 16 weeks after switching back to candesartan or telmisartan (clinic BP, morning home diastolic BP, and urinary albumin, P<0.05; morning home systolic BP, P<0.01). No subjects experienced an adverse reaction that required withdrawal from the study. No adverse reactions attributable to the study drugs were observed.

CONCLUSION: Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics.

Key numbers

20.6±6.1 mg/g Cr

Urinary Albumin Decrease

Decrease in urinary albumin in the CO group after olmesartan treatment.

74.5%

Target BP Achievement Rate Increase

Achievement rate for target clinic BP in the CO group at week 16 of olmesartan treatment.

Significant decrease

Morning Home BP Decrease

Morning home BP significantly decreased after 16 weeks of olmesartan treatment.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Comparing the effects of switching from candesartan or telmisartan to olmesartan in people with high blood pressure and type 2 diabetes

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the circadian biology brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the circadian biology brief